BioNTech loses 1,123 million in the first semester after selling fewer vaccines against Covid-19

The German laboratory BioNTech It closed the first half of 2024 with a loss of 1,122.9 million euros, a figure that differs from the net profit of 311.8 million recorded in the first half of last year, as reported by the company.

In the first six months of the yearthe sales of a German pharmaceutical company were 316.3 million euros, 78.1% less.

In this regard, BioNTech has explained that the year-on-year change was largely due to lower revenue from the sale of Covid-19 vaccines worldwide due to the change in demand from a pandemic market to an endemic seasonal market.

For his part, he emphasized that R&D expenditure until June reached 1,092.1 million euroscompared to €707.4 million in the same period last year, including €584.6 million for the three months ended June 30, a year-on-year increase of 56.6%.

Between April and June, BiNTech recorded a loss of 807.8 million euros, quadruple the ‘red numbers’ of 190.4 million euros in the second quarter of 2023, while its sales decreased by 23.2%, to 128.7 million euro

“Our revenue in the second quarter corresponds to the current demand for the seasonally endemic Covid-19 vaccine market,” said Jens Holstein, chief financial officer of BioNTech, for whom the laboratory, supported by a strong financial position, remains focused on its long-term growth strategy for the remainder of the year.

“This includes our clinical pipeline for personalized therapies, the development of our manufacturing capabilities and our capabilities to support additional late-stage trials, as well as our commercial activities,” he said.

In this way, BioNTech has consolidated its annual projections and remains confident of achieving an annual sales figure between 2,500 and 3,100 million euros. At the same time, BioNTech dedicates between 2,400 and 2,600 million euros to R&D and between 700 and 800 million euros for sales, general and administrative costs, while capital expenditure (capex) is estimated to be between 400 and 500 million euros.